RSS feed (help and list of feeds)
Notification
Search for previous notification documents
- Modafinil funding not approved. (3 pages, 40 KB) 01 Sep 2010
- August Tender Notification (5 pages, 131 KB) 31 Aug 2010
- Notification of acceptance of agreement with Fresenius Kabi. (1 page, 102 KB) 31 Aug 2010
- Notification of acceptance of agreement with API (1 page, 137 KB) 26 Aug 2010
- Approval of reference pricing of loperamide hydrochloride presentations. (1 page, 99 KB) 25 Aug 2010
- Topical anti-acne treatment (adapalene) and urea funding approved. (1 page, 23 KB) 25 Aug 2010
- Notification of acceptance of agreement with Regional Health. (1 page, 101 KB) 20 Aug 2010
- Atorvastatin listing changes (2 pages, 139 KB) 13 Aug 2010
- Donepezil funding (1 page, 133 KB) 13 Aug 2010
- Listing of sodium bicarbonate capusles (1 page, 113 KB) 13 Aug 2010
- Clopidogrel removal of Special Authority notification. (1 page, 37 KB) 12 Aug 2010
- Notification of approval of proposal for various pharmaceuticals. (6 pages, 55 KB) 09 Aug 2010
- Guidelines for Funding Applications to PHARMAC for self monitoring blood glucose (SMBG) systems approved. (2 pages, 42 KB) 03 Aug 2010
- Zoledronic acid funding approved (4 pages, 89 KB) 03 Aug 2010
- Approval of proposal for meloxicam and mitomycin C. (2 pages, 150 KB) 02 Aug 2010
- July Tender Notification (8 pages, 196 KB) 30 Jul 2010
- Notification of levetiracetam funding changes. (2 pages, 39 KB) 30 Jul 2010
- Notification of Lorstat supply delay (1 page, 75 KB) 30 Jul 2010
- Notification of ondansetron tender decisions and widening access. (2 pages, 39 KB) 30 Jul 2010
- Notification of dietitian prescribing. (1 page, 36 KB) 23 Jul 2010
Page updated on 01 Sep 2010
Linked documents
Modafinil funding not approved. (3 pages, 40 KB)
1 September 2010 Modafinil funding not approved PHARMAC has decided not to approve a provisional agreement with CSL Biotherapies (NZ) Limited for the funding of modafinil as a second-line treatment for narcolepsy, which was the subject of a consultation letter…
August Tender Notification (5 pages, 131 KB)
31 August 2010 TENDER RESULTS The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 23…
Notification of acceptance of agreement with Fresenius Kabi. (1 page, 102 KB)
31 August 2010 Agreement with Fresenius Kabi approved PHARMAC is pleased to announce the approval of an agreement with Fresenius Kabi Australia Pty Limited for the listing and supply of sodium chloride infusions. This was the subject of a consultation…
Notification of acceptance of agreement with API (1 page, 137 KB)
26 August 2010 API Consumer Brands agreement for dermatologicals approved PHARMAC is pleased to announce that the approval of an agreement with API Consumer Brands (API) for a range of dermatological products. This was the subject of a consultation letter…
Approval of reference pricing of loperamide hydrochloride presentations. (1 page, 99 KB)
25 August 2010 Approval of reference presentations pricing of loperamide hydrochloride PHARMAC is pleased to announce the approval of a proposal to reference price the subsidy of loperamide hydrochloride tablets to the subsidy of loperamide hydrochloride capsules. This was the…
Topical anti-acne treatment (adapalene) and urea funding approved. (1 page, 23 KB)
25 August 2010 Topical anti-acne treatment (adapalene) and urea funding approved PHARMAC is pleased to announce the approval of an agreement with Galderma Australia Pty Limited for adapalene 0.1% cream and gel (Differin). Differin is a topical retinoid used for…
Notification of acceptance of agreement with Regional Health. (1 page, 101 KB)
20 August 2010 Agreement with Regional Health approved PHARMAC is pleased to announce the approval of an agreement with Regional Health Limited for a range of radiological contrast media. This was the subject of a consultation letter dated 30 July…
Atorvastatin listing changes (2 pages, 139 KB)
13 August 2010 Atorvastatin listing changes PHARMAC has reached an agreement with Pfizer New Zealand Ltd to continue to fund its brand of atorvastatin (Lipitor). In summary, the effect of PHARMAC’s decision is that from 1 September 2010, Lipitor will:…
Donepezil funding (1 page, 133 KB)
13 August 2010 Donepezil funding to start from 1 November 2010 As previously notified on 5 May 2010, the PHARMAC Board approved the funding of the Donepezil-Rex brand of donepezil hydrochloride for the treatment of Alzheimer’s disease and other types…
Listing of sodium bicarbonate capusles (1 page, 113 KB)
13 August 2010 Listing of sodium bicarbonate capsules PHARMAC is pleased to announce the approval of an agreement with Aspen Pharmacare Australia Pty Ltd relating to sodium bicarbonate capsules (Sodibic). This was the subject of a consultation letter dated 2…
Clopidogrel removal of Special Authority notification. (1 page, 37 KB)
12 August 2010 Removal of Special Authority for clopidogrel PHARMAC is pleased to announce that the PHARMAC Board has approved a proposal to remove the Special Authority for funded access to clopidogrel 75 mg tablets. This was the subject of…
Notification of approval of proposal for various pharmaceuticals. (6 pages, 55 KB)
9 August 2010 Approval of proposals for various pharmaceuticals PHARMAC is pleased to announce the approval of proposals for pharmaceuticals in several therapeutic groups which aim to address some issues relating to funded access. The decision will result in, for…
Guidelines for Funding Applications to PHARMAC for self monitoring blood glucose (SMBG) systems approved. (2 pages, 42 KB)
3 August 2010 Guidelines for Funding Applications to PHARMAC for self monitoring blood glucose (SMBG) systems approved PHARMAC is pleased to announce the approval of the amended Guidelines for Funding Applications to PHARMAC for self monitoring blood glucose (SMBG) systems.…
Zoledronic acid funding approved (4 pages, 89 KB)
03 August 2010 Zoledronic acid funding approved PHARMAC is pleased to announce the approval of funding for zoledronic acid (Aclasta) for Paget’s disease and osteoporosis (including glucocorticosteroid-induced osteoporosis), subject to Special Authority criteria, from 1 September 2010 through an agreement…
Approval of proposal for meloxicam and mitomycin C. (2 pages, 150 KB)
2 August 2010 Approval of proposal for meloxicam and mitomycin C PHARMAC is pleased to announce the approval of a proposal involving the funding of meloxicam and mitomycin C through an agreement with Arrow Pharmaceuticals. This proposal was the subject…
July Tender Notification (8 pages, 196 KB)
30 July 2010 TENDER RESULTS The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 4…
Notification of levetiracetam funding changes. (2 pages, 39 KB)
30 July 2010 Listing of Levetiracetam-Rex in the Pharmaceutical Schedule and cessation of Keppra funding via Levetiracetam Special Access As previously notified on 11 July 2008, PHARMAC’s Board approved the funding of Rex Medical Ltd’s brand of levetiracetam (Levetiracetam-Rex) as…
Notification of Lorstat supply delay (1 page, 75 KB)
Facsimile To From Subject Date All Pharmacists and Wholesalers Sue Anne Yee Delay in supply of Lorstat (atorvastatin) 28 July 2010 Pages 1 Stock deliveries of Mylan’s brand of atorvastatin tablets (Lorstat), which were to be subsidised from 1 August…
Notification of ondansetron tender decisions and widening access. (2 pages, 39 KB)
30 July 2010 Notification of tender decisions for ondansetron and decision to widen funded access to ondansetron PHARMAC is pleased to announce that funded access to ondansetron will be widened from 1 May 2011, following the listing of a new…
Notification of dietitian prescribing. (1 page, 36 KB)
23 July 2010 Dietitian prescribing of special foods approved PHARMAC is pleased to announce the approval of a proposal to allow Dietitians to prescribe subsidised special foods and related products. This was the subject of a consultation letter dated 28…
